Medical Response, Search and Recovery during the Space Shuttle Columbia Accident Investigation

On February 1, 2003, the Space Shuttle Columbia broke apart during atmospheric re-entry on mission STS-107. After an event such as this, with high visibility and international interest, the operational challenge of recovering the crewmembers could not be underestimated. The Space Shuttle Program is organized to respond to a vehicle mishap using the resources of the Mishap Investigation Team (MIT). On the afternoon of Feb. 1, 2003, the MIT deployed to Barksdale Air Force Base (AFB), Louisiana. This location became the investigative center and interim storage location for crewmembers received from the Lufkin, Texas Disaster Field Office (DFO). The Lufkin DFO served as the primary area for all operations, including staging assets and deploying field teams for search, recovery and security of crewmember remains. More than 2,000 people from numerous organizations were involved with the recovery of the crew. All seven crewmembers of STS-107 were recovered and ceremonial last rights were administered. Astronaut and military personnel escorted the crew with honor to the MIT at Barksdale AFB, Louisiana. At Barksdale AFB a temporary morgue was established in an aircraft hangar and operated for approximately two weeks during which time coordination with the DFO field recovery teams, Armed Forces Institute of Pathology (AFIP) medical personnel, and the crew surgeons was on going. Families of crewmembers and NASA management were notified daily of the current findings. Working under the leadership of the MIT Lead, the medical team developed and executed a short-term plan to identify and relocate the crew with a military honor guard and protocol to the medical examiner at the Armed Forces Port Mortuary, Dover AFB, Delaware. After operations at Barksdale AFB were concluded the medical team transitioned back to Houston and a long-term plan was developed and implemented which involved the Air Force Mortuary Affairs at Randolph AFB, Texas. This plan was coordinated with search teams in the field, Barksdale AFB Mortuary Affairs, KSC security, AFIP, and the crew surgeons at JSC

John Glenn's Return to Flight - Flight Surgeons Perspective

No abstract availabl

Medical Response/Search/Recovery and Lessons Learned from the Space Shuttle Columbia Accident Investigation

No abstract availabl

Loss of Signal, Aeromedical Lessons Learned for the STS-I07 Columbia Space Shuttle Mishap

Loss of Signal, a NASA publication to be available in May 2014, presents the aeromedical lessons learned from the Columbia accident that will enhance crew safety and survival on human space flight missions. These lessons were presented to limited audiences at three separate Aerospace Medical Association (AsMA) conferences: in 2004 in Anchorage, Alaska, on the causes of the accident; in 2005 in Kansas City, Missouri, on the response, recovery, and identification aspects of the investigation; and in 2011, again in Anchorage, Alaska, on future implications for human space flight. As we embark on the development of new spacefaring vehicles through both government and commercial efforts, the NASA Johnson Space Center Human Health and Performance Directorate is continuing to make this information available to a wider audience engaged in the design and development of future space vehicles. Loss of Signal summarizes and consolidates the aeromedical impacts of the Columbia mishap process-the response, recovery, identification, investigative studies, medical and legal forensic analysis, and future preparation that are needed to respond to spacecraft mishaps. The goals of this book are to provide an account of the aeromedical aspects of the Columbia accident and the investigation that followed, and to encourage aerospace medical specialists to continue to capture information, learn from it, and improve procedures and spacecraft designs for the safety of future crews

Loss of Signal: Aeromedical Lessons Learned from the STS-107 Columbia Space Shuttle Mishap

The editors of Loss of Signal wanted to document the aeromedical lessons learned from the Space Shuttle Columbia mishap. The book is intended to be an accurate and easily understood account of the entire process of recovering and analyzing the human remains, investigating and analyzing what happened to the crew, and using the resulting information to recommend ways to prevent mishaps and provide better protection to crewmembers. Our goal is to capture the passions of those who devoted their energies in responding to the Columbia mishap. We have reunited authors who were directly involved in each of these aspects. These authors tell the story of their efforts related to the Columbia mishap from their point of view. They give the reader an honest description of their responsibilities and share their challenges, their experiences, and their lessons learned on how to enhance crew safety and survival, and how to be prepared to support space mishap investigations. As a result of this approach, a few of the chapters have some redundancy of information and authors' opinions may differ. In no way did we or they intend to assign blame or criticize anyone's professional efforts. All those involved did their best to obtain the truth in the situations to which they were assigned

Operational and Medical Procedures for a Declared Contingency Shuttle (CSCS) Shuttle Mission Due to a Failure that Precludes a Safe Return

This poster paper outlines the operational and medical procedures for a shuttle mission that has a failure that precludes a safe return to Earth. Information about the assumptions, procedures and limiting consumables is included

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

BACKGROUND: Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. METHODS: We used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes. Study-specific effect estimates per copy of each LDL-lowering allele were pooled by meta-analysis. These findings were compared with a meta-analysis of new-onset type 2 diabetes and bodyweight change data from randomised trials of statin drugs. The effects of statins in each randomised trial were assessed using meta-analysis. FINDINGS: Data were available for up to 223 463 individuals from 43 genetic studies. Each additional rs17238484-G allele was associated with a mean 0·06 mmol/L (95% CI 0·05-0·07) lower LDL cholesterol and higher body weight (0·30 kg, 0·18-0·43), waist circumference (0·32 cm, 0·16-0·47), plasma insulin concentration (1·62%, 0·53-2·72), and plasma glucose concentration (0·23%, 0·02-0·44). The rs12916 SNP had similar effects on LDL cholesterol, bodyweight, and waist circumference. The rs17238484-G allele seemed to be associated with higher risk of type 2 diabetes (odds ratio [OR] per allele 1·02, 95% CI 1·00-1·05); the rs12916-T allele association was consistent (1·06, 1·03-1·09). In 129 170 individuals in randomised trials, statins lowered LDL cholesterol by 0·92 mmol/L (95% CI 0·18-1·67) at 1-year of follow-up, increased bodyweight by 0·24 kg (95% CI 0·10-0·38 in all trials; 0·33 kg, 95% CI 0·24-0·42 in placebo or standard care controlled trials and -0·15 kg, 95% CI -0·39 to 0·08 in intensive-dose vs moderate-dose trials) at a mean of 4·2 years (range 1·9-6·7) of follow-up, and increased the odds of new-onset type 2 diabetes (OR 1·12, 95% CI 1·06-1·18 in all trials; 1·11, 95% CI 1·03-1·20 in placebo or standard care controlled trials and 1·12, 95% CI 1·04-1·22 in intensive-dose vs moderate dose trials). INTERPRETATION: The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition. FUNDING: The funding sources are cited at the end of the paper

Considerations for Medical Transport from the Space Station via an Assured Crew Return Vehicle (ACRV)

In developing a permanently crewed space station, the importance of medical care has been continually reaffirmed; and the health maintenance facility (HMF) is an integral component. It has diagnostic, therapeutic, monitoring, and information management capability. It is designed to allow supportive care for: (1) non-life-threatening illnesses; e.g., headache, lacerations; (2) moderate to severe, possibly life-threatening illnesses; e.g., appendicitis, kidney stones; and (3) severe, incapacitating, life-threatening illnesses; e.g., major trauma, toxic exposure. Since the HMF will not have a general surgical capability, the need for emergency escape and recovery methods has been studied. Medical risk assessments have determined that it is impossible to accurately predict the incidence of crewmember illness/injury. A best estimate is 1:3 per work-year, with 1% of these needing an ACRV. For an eight-person crew, this means that one assured crew return vehicle (ACRV) will be used every 4 to 12 years. The ACRV would serve at least three basic objectives as: (1) a crew return if the space shuttle is unavailable; (2) an escape vehicle from a major time-critical space station emergency; and (3) a full or partial crew return vehicle for a medical emergency. The focus of this paper is the third objective for the ACRV

Physiologic Effects of Simulated +Gx Orbital Reentry in Primate Models of Hemorrhagic Shock

Introduction: While the physiologic effects of space travel are documented in healthy individuals, little is known about its impact on medically ill or injured persons. In this study, hemorrhagic shock in primates was used to model a potentially common pathophysiologic condition during exposure to gravitational forces simulating return from Earth orbit. This experiment did not model the effects of cardiovascular deconditioning that normally occur during spaceflight. Methods: Using invasive hemodynamic monitoring, serial cardiovascular and laboratory parameters in baboons (Papio papio) were studied. Subjects were centrifuged at either a low +Gx (3.3 G maximum) or high +Gx (7.8 G maximum) acceleration reentry profile before and after being subjected to either class II (20% volume loss) or class IV (40% volume loss) hemorrhagic shock. Results: Significant alterations in cardiovascular and laboratory parameters occurred during shock and exposure to high and low +Gx acceleration. Shock classification was the primary determinant of change in cardiovascular function. During the experimental protocol, 31 of 32 animals survived (97% survival). After a 1-wk post-protocol observation period, 28 of 32 subjects survived (88% survival).Conclusions: This preliminary study presents data that suggest that the emergent return of a medically compromised individual without resuscitation may be potentially survivable. However, medical stabilization with volume resuscitation, supplemental oxygen, and noninvasive monitoring would likely optimize clinical outcomes in the event of significant hemorrhagic shock states necessitating emergent deorbit

Physiologic Effects of Simulated +Gx Orbital Reentry in Primate Models of Hemorrhagic Shock

Introduction: While the physiologic effects of space travel are documented in healthy individuals, little is known about its impact on medically ill or injured persons. In this study, hemorrhagic shock in primates was used to model a potentially common pathophysiologic condition during exposure to gravitational forces simulating return from Earth orbit. This experiment did not model the effects of cardiovascular deconditioning that normally occur during spaceflight. Methods: Using invasive hemodynamic monitoring, serial cardiovascular and laboratory parameters in baboons (Papio papio) were studied. Subjects were centrifuged at either a low +Gx (3.3 G maximum) or high +Gx (7.8 G maximum) acceleration reentry profile before and after being subjected to either class II (20% volume loss) or class IV (40% volume loss) hemorrhagic shock. Results: Significant alterations in cardiovascular and laboratory parameters occurred during shock and exposure to high and low +Gx acceleration. Shock classification was the primary determinant of change in cardiovascular function. During the experimental protocol, 31 of 32 animals survived (97% survival). After a 1-wk post-protocol observation period, 28 of 32 subjects survived (88% survival).Conclusions: This preliminary study presents data that suggest that the emergent return of a medically compromised individual without resuscitation may be potentially survivable. However, medical stabilization with volume resuscitation, supplemental oxygen, and noninvasive monitoring would likely optimize clinical outcomes in the event of significant hemorrhagic shock states necessitating emergent deorbit